Top Markets
Coin of the day
GBS Inc. GBS Inc.

GBS Inc.

GBS
Rangering i aksjer #33716
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Aksjekurs
$0.4732
Sist synkronisert: 2022-10-26
Markedsverdi
$7.05M
Endring (1 dag)
-0.03%
Endring (1 år)
0.00%
Land
US
Handel GBS Inc. (GBS)

Kategori

P/B-forhold for GBS Inc. (GBS)
P/B-forhold per 2026 TTM: 0
Ifølge GBS Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for GBS Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
3.7944 -
US
5.423 -
US
2.0146 -
IE
3.072 -
US
4.9725 -
US